Stock GNTA GENENTA SCIENCE S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up

All News Genenta Science S.p.A.

Equities

GNTA

US36870W1009

Market Closed - Nasdaq
Other stock markets
 02:00:00 30/04/2024 am IST 		5-day change 1st Jan Change
2.95 USD +13.90% Intraday chart for Genenta Science S.p.A. -25.25% -40.40%
08/04 Genenta Science S.P.A. Announces Resignation of Board Members CI
29/03 Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Genenta Science S.P.A. Announces Resignation of Board Members
CI
Genenta Science S p A : NOTICE OF CALL OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING - Form 6-K
PU
Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
GL
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
AQ
Genenta Science Demonstrated Reprogramming of the Tumor Microenvironment in Gbm Patients, Paving the Way for Innovative Treatments of Solid Tumors
CI
Sandoz to Acquire Cimerli Business from Coherus for $170 Million
DJ
Genenta Science S p A : Consolidated Statements of Operations and Comprehensive Loss - Form 6-K
PU
Genenta Science S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Genenta to Present at Upcoming Scientific and Investor Conferences
GL
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
GL
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
AQ
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
CI
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma
GL
Health Care Stocks Support American Depositary Receipts of European Equities
MT
Genenta to Provide Update on Lead Product Temferon™
AQ
Genenta Science S p A : NOTICE OF CALL OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING - Form 6-K
PU
Genenta Science S p A : Effectiveness of the Amended and Restated OSR License Agreement - Form 6-K
PU
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing
GL
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GNTA Stock
  4. News Genenta Science S.p.A.